Cargando…

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination

Tuberculosis (TB) is a major global health problem and the only currently-licensed vaccine, BCG, is inadequate. Many TB vaccine candidates are designed to be given as a boost to BCG; an understanding of the BCG-induced immune response is therefore critical, and the opportunity to relate this to circ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bitencourt, Julia, Peralta-Álvarez, Marco Polo, Wilkie, Morven, Jacobs, Ashley, Wright, Daniel, Salman Almujri, Salem, Li, Shuailin, Harris, Stephanie A., Smith, Steven G., Elias, Sean C., White, Andrew D., Satti, Iman, Sharpe, Sally S., O’Shea, Matthew K., McShane, Helen, Tanner, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767055/ https://www.ncbi.nlm.nih.gov/pubmed/35069580 http://dx.doi.org/10.3389/fimmu.2021.798207

Ejemplares similares

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
por: Satti, Iman, et al.
Publicado: (2022)

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
por: Harris, Stephanie A., et al.
Publicado: (2018)

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study
por: Wilkie, Morven, et al.
Publicado: (2022)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

TB vaccine development: where are we and why is it so difficult?
por: Wilkie, Morven E M, et al.
Publicado: (2015)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
por: Tanner, Rachel, et al.
Publicado: (2021)

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
por: Minhinnick, Alice, et al.
Publicado: (2016)

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
por: Tanner, Rachel, et al.
Publicado: (2021)

BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients
por: Ashenafi, Senait, et al.
Publicado: (2013)

Editorial Commentary: Understanding BCG Is the Key to Improving It
por: McShane, Helen
Publicado: (2014)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica
por: Chihara, Norio, et al.
Publicado: (2013)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2016)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
por: Wilkie, Morven, et al.
Publicado: (2020)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2019)

Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma
por: Choi, Qute, et al.
Publicado: (2010)

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation
por: Sibley, Laura, et al.
Publicado: (2021)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, Magali, et al.
Publicado: (2014)

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
por: Tanner, Rachel, et al.
Publicado: (2020)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease
por: Lin, Wei, et al.
Publicado: (2017)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
por: O’Shea, Matthew K., et al.
Publicado: (2018)

A review of clinical models for the evaluation of human TB vaccines
por: O'Shea, Matthew K., et al.
Publicado: (2016)

Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods
por: Rhodes, Sophie J., et al.
Publicado: (2017)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells
por: Tanner, Rachel, et al.
Publicado: (2019)

Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation
por: Joo, HyeMee, et al.
Publicado: (2012)

Proliferative glomerulonephritis with monoclonal IgG Lambda deposits caused by plasmablastic lymphoma: a case report
por: Ren, Ling-Yan, et al.
Publicado: (2023)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Plasmablastic lymphoma in Malawi
por: Zuze, Takondwa, et al.
Publicado: (2018)

Orbital plasmablastic lymphoma
por: Bloch, Edward, et al.
Publicado: (2017)

Plasmablastic lymphoma: An update
por: Bailly, Jenique, et al.
Publicado: (2022)

Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder
por: Ramadas, Poornima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hmuku5bcn3thpdgb7vc7papd5j